BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Selvita to Release the Most Recent Results from its Oncology Programs at the 2011 American Association for Cancer Research-European Organization for Research and Treatment of Cancer-National Cancer Institute Molecular Targets and Cancer Therapeutics Conference


10/24/2011 10:37:24 AM

Krakow, Poland, October 24, 2011 / B3C newswire / - Selvita, Polish biotechnology company engaged in the discovery and development of breakthrough medicines to treat CNS and oncology disorders, as well as provision of non-clinical research services, announced today that data from two of its oncology programs is scheduled to be reported at the 2011 AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference, November 12-16, 2011, in San Francisco, CA, USA.

Data presented during this conference will include new results from the SEL24 program, a group of specific inhibitors of Pim-1 kinase, as well as the first data from SEL120 program, a potentially first in class kinase inhibitor.

A poster presentation entitled "Novel Pim kinase inhibitors for treatment of hematological malignancies and solid tumors" is scheduled to be presented at the poster session A, titled "Therapeutic Agents: Small Molecule Kinase Inhibitors 1" on Sunday, November 13th, 2011 from 12:30 PM - 2:30 PM, at the West Hall, Level One, Moscone Center West (Abstract #: A243)

A poster presentation entitled " Antitumor activity of SEL120: An orally available small-molecule inhibitor of Haspin kinase, for standalone and combination therapy with AuroraB inhibitors in colorectal cancer" is scheduled to be presented at the poster session B, titled "Therapeutic Agents: Small Molecule Kinase Inhibitors 2" Monday, November 14th, 2011 from 12:30 PM - 2:30 PM, at the West Hall, Level One, Moscone Center West (Abstract # B242).

“Current and further development of both SEL24 and SEL120 program, presented at the AACR-EORTC-NCI conference, was made possible thanks to the substantial investment received by Selvita through private placement and the debut on the NewConnect market in July 2011– said Dr Nicolas Beuzen, Selvita’s Chief Scientific Officer. SEL24 is currently at the lead optimization stage, with first clinical trials to be initiated in 2012, while SEL120 is currently in the early phase of discovery research. Selvita’s strategy assumes sales of both programs, SEL24 in 2012 and SEL120 in the following years, which will allow the company to break-even in 2012.”

About Selvita

Selvita is a Polish, biotechnology company engaged in the discovery and development of breakthrough medicines to treat CNS and oncology disorders, as well as provision of non-clinical research services. It was established and 2007 and currently employs 125 scientists, including 45 PhDs. Selvita has currently several projects at early or late discovery stage and is expected to move its first candidates to the clinic in 2012. The most advanced programs at Selvita are SEL103 for the symptomatic treatment of Alzheimer’s disease, partnered with Orion Pharma, and SEL24, a pre-clinical Pim kinase inhibitor, with multiple indications in solid and hematopoietic tumors. Additional information about Selvita can be found on http://www.selvita.com/.

Media contact

Natalia Pawela

natalia.pawela@selvita.com

+48 12 297 47 31



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES